New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Private company trial initiations stand out in the latest week’s disclosures.
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.
A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
Despite magrolimab’s latest flop, efforts to target CD47 continue.
The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.